Equities

Jiangsu Bioperfectus Technologies Co Ltd

688399:SHH

Jiangsu Bioperfectus Technologies Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)80.93
  • Today's Change-0.57 / -0.70%
  • Shares traded1.13m
  • 1 Year change+47.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jiangsu Bioperfectus Technologies Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic products. The Company's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The Company mainly conducts its businesses in domestic and overseas markets.

  • Revenue in CNY (TTM)394.84m
  • Net income in CNY-170.68m
  • Incorporated2010
  • Employees684.00
  • Location
    Jiangsu Bioperfectus Technologies Co LtdNo. 837, Yaocheng AvenueTAIZHOU 225300ChinaCHN
  • Phone+86 52 380225599
  • Fax+86 52 386201617
  • Websitehttps://www.bioperfectus.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sino Medical Sciences Technology Inc417.13m-4.63m4.24bn652.00--4.95--10.17-0.0112-0.01121.012.070.34981.4533.50639,765.50-0.3445-4.21-0.411-4.7160.2270.96-0.985-15.761.61--0.1327--77.99-2.0475.59---7.30--
Getein Biotech Inc1.25bn252.99m4.37bn2.14k17.261.68--3.500.49880.49882.465.120.32411.622.91584,007.906.7313.259.8618.4567.6465.5720.7628.131.69--0.20529.88-24.8514.81-43.922.3118.446.00
Qingdao NovelBeam Technology Co Ltd413.02m124.91m4.40bn797.0035.173.43--10.661.041.043.4410.630.29620.86634.68518,221.708.8114.679.3716.6363.8562.3229.7334.159.12--0.026233.55-1.3118.58-20.1921.7110.45--
Jiangsu Bioperfectus Technologies Co Ltd394.84m-170.68m4.59bn684.00--1.40--11.62-2.91-2.916.7458.000.0970.97472.52577,244.10-4.1925.41-4.7431.2665.7063.37-43.2332.864.96--0.090330.54-92.7211.81-120.45--2.43--
TINAVI Medical Technologies Co Ltd168.49m-160.48m4.60bn339.00--3.90--27.29-0.3585-0.35850.37562.620.10751.484.73475,961.90-10.24-7.86-11.04-9.0768.6673.58-95.24-50.092.21--0.1532--34.4810.63-41.42--51.87--
Assure Tech Hangzhou Co Ltd590.49m90.50m4.80bn791.0053.040.9316--8.130.7120.7124.6540.530.10111.902.85746,504.601.5531.831.7138.9736.8765.8215.3047.868.66--0.012516.05-91.8425.18-95.3533.5178.77--
Beijing Chunlizhengda Mdicl Instr Co Ltd924.65m158.35m4.82bn1.23k34.751.94--5.210.40780.40782.417.290.26980.53812.15751,138.904.6212.535.4915.4371.0872.7617.1226.893.80--0.000321.630.575919.40-9.7221.33-8.60--
Zhejiang Gongdong Medical Techno Co Ltd1.10bn162.27m4.90bn1.67k30.172.94--4.461.031.036.9510.570.56846.554.33656,174.208.4016.359.7119.2632.4841.1914.7721.623.00--0.052138.99-33.6115.11-66.535.1427.71--
Hangzhou Ags Medtech Co Ltd590.12m271.52m4.95bn592.0018.212.15--8.393.363.367.3028.530.25453.2713.92996,828.3011.71--12.26--71.52--46.01--19.56--0.003--37.09--49.87------
Data as of Nov 15 2024. Currency figures normalised to Jiangsu Bioperfectus Technologies Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.56%Per cent of shares held by top holders
HolderShares% Held
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 202496.50k0.17%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 202492.97k0.16%
Penghua Fund Management Co., Ltd.as of 30 Jun 202464.73k0.11%
China Merchants Fund Management Co., Ltd.as of 30 Jun 202413.61k0.02%
GF Fund Management Co., Ltd.as of 30 Jun 202411.99k0.02%
Acadian Asset Management LLCas of 30 Sep 202311.51k0.02%
Dimensional Fund Advisors LPas of 03 Oct 202410.57k0.02%
Tian Hong Asset Management Co., Ltd.as of 30 Jun 20249.92k0.02%
China Southern Asset Management Co., Ltd.as of 30 Jun 20247.52k0.01%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 20246.10k0.01%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.